Combination of methylselenocysteine with tamoxifen inhibits MCF-7 breast cancer xenografts in nude mice through elevated apoptosis and reduced angiogenesis

Autor: Virgilio A. Salvo, Aditi Belame, Brian G. Rowan, Arunthavarani Thiyagarajah, Matthew E. Burow, Zengshan Li, Latonya Carrier
Rok vydání: 2008
Předmět:
Cancer Research
medicine.medical_specialty
Neoplasms
Hormone-Dependent
Mice
Nude
Angiogenesis Inhibitors
Apoptosis
Breast Neoplasms
Adenocarcinoma
chemistry.chemical_compound
Mice
Random Allocation
Cyclin D1
Internal medicine
Organoselenium Compounds
Antineoplastic Combined Chemotherapy Protocols
medicine
Animals
Humans
Cysteine
skin and connective tissue diseases
Estradiol
Neovascularization
Pathologic
business.industry
Estrogen Receptor alpha
Cancer
Drug Synergism
medicine.disease
Antiestrogen
Xenograft Model Antitumor Assays
Neoplasm Proteins
Selenocysteine
Specific Pathogen-Free Organisms
Methylselenocysteine
Gene Expression Regulation
Neoplastic
Tamoxifen
Endocrinology
Oncology
chemistry
MCF-7
Selective estrogen receptor modulator
Cancer research
Female
Breast disease
business
Receptors
Progesterone
Cell Division
medicine.drug
Zdroj: Breast cancer research and treatment. 118(1)
ISSN: 1573-7217
Popis: To investigate the therapeutic effect of methylselenocysteine (MSC) combined with tamoxifen in MCF-7 breast cancer xenograft and the underlying mechanisms. MCF-7 breast cancer xenograft was established in ovariectomized female athymic nude mice and treated with tamoxifen and/or MSC. Tumor size was measured twice a week. Immunohistochemistry and TUNEL assays were used to measure ERalpha expression, ERalpha target genes (progesterone receptor (PR) and cyclin D1 expression), Ki-67 index, apoptosis and microvessel density. Combined treatment with tamoxifen and MSC synergistically inhibited tumor growth compared to MSC alone and tamoxifen alone. MSC alone or MSC + tamoxifen significantly reduced ERalpha, PR and cyclin D1, Ki67 index and microvessel density while increasing apoptosis in tumor tissues. These findings demonstrate synergistic growth inhibition of ERalpha positive breast cancer xenografts by combination of tamoxifen with organic selenium compounds. Organic selenium may provide added benefit when combined with tamoxifen in adjuvant therapy or prevention.
Databáze: OpenAIRE
Externí odkaz: